Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
Peptides sold in the research-chemical channel are labeled for laboratory use, are not manufactured to pharmaceutical identity or purity standards, and cannot be assumed to match the trial material in content, dose, or purity
IGF-1 LR3 1mg A recombinant analog of insulin-like growth factor 1 (IGF-1) with an extended half-life due to amino acid substitutions, studied in preclinical research for its direct anabolic effects on muscle tissue, cellular proliferation, and metabolic regulation independent of growth hormone stimulation
Mounjaro is licensed for type 2 diabetes and for weight management for people living with obesity, or with overweight and at least one weight-related health condition
Pharmacology and clinical development of GIP/GLP-1/glucagon triple agonists
Contact Information The following contact details are published on the official SkinnyRx website: Platform: SkinnyRx Address: 2108 N ST STE N, Sacramento, CA 95816 Phone: 1 (888) 979-9580 Email: [email protected] View the current SkinnyRx offer (official SkinnyRx page) Disclaimers Content and Medical Disclaimer: This is an informational overview and is not a substitute for professional medical advice, diagnosis, or treatment
When the Breakthrough Obesity G-Agonist Drugs Exceed Expectations The expanding GLP-1 family of drugs and their expanded potential use cases Back last December I wrote about the The New Obesity Breakthrough Drugs, and specifically the striking results in randomized trials for semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight loss, their putative mechanism(s), while also emphasizing their very high cost, lack of plan for successful weaning, and exacerbation of health inequities
